Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

Background: Bruton tyrosine kinase inhibitors (BTKi) are used in B-cell malignancies and in development against various autoimmune diseases. Since Btk is also involved in specific pathways of platelet activation, BTKi might be considered to target platelet GPVI/GPIb-mediated atherothrombosis and pla...

Full description

Bibliographic Details
Main Authors: Rundan Duan, Luise Goldmann, Richard Brandl, Michael Spannagl, Christian Weber, Wolfgang Siess, Philipp von Hundelshausen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
atherothrombosis
platelet-aggregation
bleeding
PFA
MEA
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.749022/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2021.749022/full

Similar Items